Role of Definitive Surgery for Ulcerative Colitis in the Current Era of Evolving Biological Therapy

B. Subtotal colectomy followed by staged reconstruction

Often used in emergency or high-risk settings.

C. Ileorectal anastomosis

In carefully selected patients with a relatively healthy rectum and acceptable sphincter function.

This preserves the rectum but requires continued surveillance because residual rectal mucosa remains.

D. IPAA

The most established restorative option for many suitable patients with UC.

---

8. Why Is Staged Surgery Important in the Modern Biological Era?

Patients reaching surgery after multiple biologics may have additional challenges.

They may have:

• Chronic inflammation
• Anaemia
• Hypoalbuminemia
• Weight loss
• Steroid exposure
• Immunosuppression
• Increased infection risk
• Poor physiological reserve

Trying to perform a complex restorative operation in a severely inflamed, malnourished or systemically ill patient may not be the safest strategy.

Therefore, staged surgery can be advantageous.

A common pathway in a high-risk or emergency patient is:

Stage 1 → Subtotal colectomy + end ileostomy

↓

Patient recovery + nutritional optimisation

↓

Stage 2 → Completion proctectomy + IPAA

↓

Stage 3 → Ileostomy closure

The exact pathway should be individualized.

---

9. What About Biologics Before Surgery?

This is an increasingly important question.

A patient receiving biologic therapy should not automatically be denied surgery because of the medication.

Conversely, biologic therapy should not automatically be continued or stopped without considering the specific drug, timing, disease activity and operative plan.

The 2026 ECCO surgical guideline emphasizes individualized perioperative optimization. It notes that evidence differs between biologic classes and that evidence for some newer small-molecule therapies remains less definitive. The guideline suggests individualized timing, with surgery often planned toward the end of a biologic dosing interval when feasible.

The more important issue is often not simply:

“Is the patient on a biologic?”

but:

“What is the patient’s nutritional, inflammatory and immunological condition at the time of surgery?”

Preoperative optimization should include assessment of:

• Nutrition
• Albumin
• Anaemia
• Electrolytes
• Infection
• Steroid exposure
• Disease activity
• Thromboembolic risk
• Medication timing
• Stoma education

---

10. The Steroid Problem: A Major Reason Not to Delay Surgery

Steroids remain useful for controlling acute inflammation, but prolonged steroid dependence is problematic.

A patient who repeatedly requires:

Prednisolone → taper → relapse → prednisolone again

has not achieved a satisfactory long-term treatment strategy.

Chronic steroid exposure can contribute to:

• Infection
• Diabetes
• Osteoporosis
• Muscle wasting
• Poor wound healing
• Adrenal suppression
• Increased perioperative risk

Therefore, continuing steroids indefinitely simply to avoid surgery may sometimes create greater cumulative risk than appropriately timed elective surgery.

---

11. The “Fourth, Fifth or Sixth Drug” Question

This is where shared decision-making becomes crucial.

Suppose a patient has failed:

• Steroids
• Immunomodulator
• Anti-TNF
• Vedolizumab
• Ustekinumab
• An IL-23 inhibitor

Should another medication automatically be tried?

Not necessarily.

There may still be a legitimate medical option in a selected patient.

But the decision must consider:

Probability of benefit

versus

Cost of continued disease

versus

Risk of delaying surgery

versus

Expected quality of life after surgery

This is a fundamentally different decision from simply asking whether another drug exists.

---

12. Surgery Is Not a “Failure of Medical Treatment”

This deserves emphasis.

Patients sometimes believe:

“If I need surgery, my medicines have failed and I have lost the battle.”

That is not an accurate way to understand UC.

UC is a disease in which both medical and surgical treatments are legitimate definitive components of care.

Biological therapy attempts to control the immune-mediated inflammatory process while preserving the colon.

Definitive surgery removes the organ in which the disease is occurring.

For appropriately selected patients, surgery can therefore be viewed as:

a definitive treatment—not a treatment failure.

---

13. What Can Surgery Achieve That Medicines Cannot?

This is the central reason surgery remains relevant in 2026.

Successful definitive surgery can:

• Remove the diseased colon
• Eliminate colonic UC activity
• Stop recurrent colitis-related bleeding
• Eliminate the need for chronic UC medication in many patients
• Remove the diseased colon at risk of dysplasia/cancer
• Reduce repeated hospitalizations
• End the cycle of steroid dependence
• Provide durable symptom control

The 2026 ECCO guideline specifically notes that appropriately timed surgery can resolve debilitating symptoms, eliminate the need for chronic medical therapy and recurrent hospitalizations, and reduce malignancy risk.

---

14. But Surgery Is Not “A Cure Without Trade-Offs”

Definitive surgery has its own consequences.

Patients considering proctocolectomy and IPAA must understand that:

• Bowel frequency may remain higher than in individuals without surgery
• Stool consistency changes
• Urgency may occur
• Pouchitis can develop
• Small-bowel obstruction can occur
• Sexual and reproductive considerations are relevant
• Pouch failure, although uncommon, is possible
• Some patients may ultimately require permanent diversion

The 2026 ECCO guideline therefore emphasizes comprehensive counseling and shared decision-making rather than presenting surgery as a universally superior option.

Long-term studies nevertheless demonstrate that IPAA can provide good functional and quality-of-life outcomes in appropriately selected patients.

---

15. Why Surgical Timing Matters More Than Ever

One of the most important concepts in modern UC surgery is:

“Do not wait until the patient becomes a poor surgical candidate.”

A patient undergoing planned elective surgery after optimization is very different from a patient undergoing emergency colectomy after:

• Severe sepsis
• Toxic megacolon
• Massive bleeding
• Severe hypoalbuminemia
• Prolonged high-dose steroids
• Multiple failed rescue therapies

The 2026 ECCO guideline emphasizes that early surgery after optimized medical therapy is associated with better recovery and that delaying surgery may increase the likelihood of emergency surgery and postoperative morbidity.

Therefore:

Early surgical consultation does not mean early surgery.

It means:

early preparation for the possibility of surgery.

---

16. Minimally Invasive Surgery Has Changed the Surgical Equation

Modern UC surgery is not the same operation it was decades ago.

Laparoscopic and robotic techniques can allow:

• Smaller incisions
• Reduced postoperative pain
• Earlier mobilization
• Shorter hospitalization
• Better cosmetic outcomes
• Potentially fewer adhesions and incisional complications

The 2026 ECCO guideline recommends minimally invasive surgery for medically refractory UC when expertise is available.

Population-level data also show a substantial increase in minimally invasive surgery over time, with lower complication rates reported for laparoscopic compared with open procedures in a large German dataset.

---

17. The Importance of an Experienced IBD Surgical Centre

UC surgery is not simply about removing the colon.

The surgeon must understand:

• IBD biology
• Emergency colectomy
• Restorative proctocolectomy
• Pelvic dissection
• IPAA
• Pouch complications
• Pouch salvage
• Stoma creation and reversal
• Fertility considerations
• Sexual function
• Cancer surgery
• Perioperative nutrition
• Immunosuppressive therapy

The 2026 ECCO surgical guideline recommends restorative proctectomy in specialized IBD centres and highlights the importance of institutional experience with IPAA.

---

18. Biologics and Surgery Should Not Be Viewed as Opponents

The modern UC pathway is better represented as:

Diagnosis

↓

Risk stratification

↓

Optimized medical therapy

↓

Treat-to-target assessment

↓

Clinical + biochemical + endoscopic response

↙︎ ↘︎

Durable remission Persistent active disease

↓ ↓

Continue medical Multidisciplinary
strategy surgical assessment

↓ ↓

Long-term monitoring Elective surgery when appropriate

This is the modern philosophy.

---

19. When Definitive Surgery Becomes the More Rational Option

A patient becomes a stronger surgical candidate when several of the following are present:

Clinical situation	Why surgery deserves serious consideration
Steroid dependence	Indicates inability to maintain remission without corticosteroids
Steroid resistance	Suggests difficult-to-control disease
Multiple advanced therapy failures	Declining probability of durable medical control
Persistent endoscopic inflammation	Indicates incomplete disease control
Recurrent hospitalization	Significant ongoing disease burden
Severe anaemia	Marker of ongoing inflammatory/bleeding burden
Malnutrition/hypoalbuminemia	Delays recovery and increases operative risk
Acute severe colitis	Surgery may become life-saving
Toxic megacolon	Risk of perforation and systemic deterioration
Perforation	Surgical emergency
Dysplasia	Cancer prevention becomes a major objective
Colorectal cancer	Requires oncological treatment
Poor quality of life	Symptoms remain unacceptable despite medical therapy

---

20. A Particularly Important 2026 Concept: “Medical Failure” Is Not Just Drug Failure

A patient may technically have “another drug option.”

But that does not automatically mean another drug is the best option.

Medical failure should be considered in a broader sense.

Medical failure may include:

Failure to achieve remission

or

Failure to maintain steroid-free remission

or

Failure to achieve meaningful endoscopic control

or

Repeated treatment-related toxicity

or

Repeated hospitalization

or

Unacceptable impact on quality of life

or

Progression toward dysplasia/cancer

Thus:

The availability of another medication does not necessarily mean that another medication is the best treatment.

---

21. The Patient’s Quality of Life Must Be Part of the Surgical Decision

Traditional clinical decision-making often focuses on:

• Mayo score
• CRP
• Endoscopy
• Haemoglobin
• Stool frequency

But patients may be more concerned about:

• “Can I sleep through the night?”
• “Can I travel?”
• “Can I attend work?”
• “Can I leave home without knowing where the toilet is?”
• “How many years can I continue taking steroids?”
• “How many hospital admissions can I tolerate?”
• “Do I want to remain dependent on medicines indefinitely?”

The 2026 ECCO guideline specifically emphasizes functional outcomes such as nocturnal bowel movements, urgency, sleep disruption, work productivity, travel and social participation when discussing surgery.

This represents an important evolution:

The endpoint of treatment is not merely “colon preservation.”

It is:

a healthy, functional and meaningful life.

---

22. Definitive Surgery and Cancer Prevention

Long-standing extensive UC is associated with increased colorectal neoplasia risk.

Therefore, when dysplasia or cancer develops, the therapeutic equation changes.

The 2026 ECCO surgical guideline recommends oncological proctocolectomy, with or without pouch formation depending on the clinical circumstances, as the principal surgical strategy when colorectal cancer or significant dysplasia is present, while recognizing selected situations in which more limited treatment may be appropriate.

In these patients, surgery is no longer simply about controlling symptoms.

It becomes:

cancer treatment + risk reduction + disease control.

---

23. What Should Patients Ask Before Choosing Surgery?

A patient considering definitive UC surgery should ask the multidisciplinary team:

About the disease

1. How severe is my current disease?
2. Is there objective endoscopic inflammation?
3. Am I steroid-dependent?
4. Have I genuinely failed my current advanced therapy?
5. What is the probability that another therapy will provide durable remission?

About surgery

6. Do I need surgery now or can it safely be planned?
7. Would I need a staged operation?
8. Am I a candidate for IPAA?
9. Would a permanent ileostomy be more appropriate?
10. What bowel function can I realistically expect?

About the surgeon and centre

11. How frequently does the centre perform UC surgery?
12. How frequently are IPAA procedures performed?
13. How are pouch complications managed?
14. Is there multidisciplinary IBD care?

About the future

15. How will surgery affect work and travel?
16. What are the implications for fertility and sexual function?
17. Will I require long-term medications after surgery?
18. What happens if pouchitis develops?
19. What is the plan for long-term follow-up?

---

24. The 2026 Treatment Philosophy: “Right Drug, Right Patient, Right Time—and Right Surgery”

The modern management of ulcerative colitis should not be framed as a competition between gastroenterology and surgery.

It should be a continuum:

Medical therapy

Preserves the colon when durable disease control is achievable.

Surgery

Provides definitive control when the disease becomes medically refractory, dangerous, dysplastic or unacceptable to the patient.

The best outcomes occur when the two approaches are integrated.

---

25. Key Take-Home Messages

1. Biologics have changed UC treatment—but have not eliminated surgery.

Advanced therapies have reduced colectomy risk in some populations, but a significant group of patients continues to require surgery.

2. More drugs do not automatically mean surgery should be delayed.

The probability of meaningful response, cumulative drug exposure, disease burden and surgical risk must all be considered.

3. Surgery should be discussed early.

Early surgical consultation allows optimization and informed decision-making without committing the patient to immediate surgery.

4. Emergency surgery should be avoided whenever safely possible.

Elective surgery generally offers a more controlled environment than emergency colectomy.

5. Definitive surgery can provide durable disease control.

Total proctocolectomy removes the colon and rectum affected by UC and may eliminate the need for chronic UC medication.

6. IPAA can restore intestinal continuity in appropriately selected patients.

However, patients must understand pouch-related functional outcomes and potential complications.

7. Surgical expertise matters.

Modern UC surgery should ideally be performed in experienced centres with multidisciplinary IBD care.

8. The goal is not simply to avoid colectomy.

The goal is:

steroid-free remission + durable disease control + cancer prevention + good quality of life.

---

Conclusion

Has biological therapy made definitive surgery obsolete in ulcerative colitis?

No.

It has made the decision more sophisticated.

In 2026, a patient with UC may have multiple advanced medical options before surgery is considered. The expanding range of biologics, IL-23 inhibitors, JAK inhibitors and S1P modulators provides genuine opportunities to achieve remission without an operation.

But when disease remains medically refractory, when steroids cannot be withdrawn, when repeated hospitalizations continue, when severe complications develop, or when dysplasia or cancer appears, definitive surgery remains one of the most powerful treatments available.

The modern approach should therefore not be:

“Use every possible drug before surgery.”

It should be:

“Use effective medical therapy intelligently, monitor objectively, involve the surgeon early, and perform definitive surgery at the right time when surgery offers the better long-term outcome.”

In the current era, surgery is not the failure of biologic therapy. Surgery is an integral part of the complete treatment strategy for ulcerative colitis.

---

Clinical Decision Algorithm

Patient with moderate-to-severe UC

↓

Optimized advanced medical therapy

↓

Assess clinical + biochemical + endoscopic response

If adequate steroid-free remission:

→ Continue medical therapy
→ Treat-to-target monitoring
→ Surveillance as appropriate

If partial/inadequate response:

→ Reassess diagnosis, adherence, drug exposure and disease severity
→ Consider optimized or alternative advanced therapy
→ Early colorectal surgical consultation

If persistent severe disease despite optimized therapy:

→ Discuss elective definitive surgery

If acute severe colitis with deterioration/rescue failure:

→ Urgent multidisciplinary surgical decision

If toxic megacolon/perforation/uncontrolled bleeding:

→ Emergency surgery

If dysplasia/cancer:

→ Oncological surgical assessment

---

Evidence & References

1. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment, 2026. Journal of Crohn’s and Colitis. The latest ECCO surgical guideline addresses medically refractory UC, acute severe colitis, surgical timing, minimally invasive surgery, IPAA and perioperative optimization.
2. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment, 2026. Provides contemporary evidence for anti-TNF therapy, vedolizumab, ustekinumab, IL-23 inhibitors, JAK inhibitors and S1P modulators.
3. Berlet M, et al. Trends in surgical treatment for ulcerative colitis in the era of biologics. Surgery. 2025. Population-based German analysis demonstrating continued need for colectomy despite increasing use of biologics and increasing adoption of minimally invasive surgery.
4. Tukek NB, et al. The effects of biologics on ulcerative colitis-related colectomy rate: results of a 22-year study. Scandinavian Journal of Gastroenterology. 2025. Demonstrated lower colectomy rates in the biological era, while identifying steroid resistance/dependence and persistent mucosal inflammation as important predictors.
5. Dai N, et al. Colectomy rates in ulcerative colitis: a systematic review and meta-analysis. Digestive and Liver Disease. 2022. Review of more than 294,000 patients examining long-term colectomy rates and the biological era.
6. American Society of Colon and Rectal Surgeons. Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. Surgical guidance covering severe medically refractory disease, fulminant colitis, toxic megacolon and perforation.

---

Medical Disclaimer

This article is intended for advanced patient education and professional knowledge purposes. The decision to continue medical therapy, change advanced therapy or undergo surgery for ulcerative colitis must be individualized and should involve an experienced gastroenterologist and colorectal/IBD surgeon. The availability and regulatory approval of specific medicines may differ between countries and over time.

Last reviewed: August 2026